. . "[8B929C573126]" . "1211-264X" . "7"^^ . "Invazivn\u00ED mukormyk\u00F3za u d\u011Btsk\u00FDch hematoonkologick\u00FDch pacient\u016F: zku\u0161enosti 2005-2010" . "\u0160najdauf, Ji\u0159\u00ED" . . . . "Klinick\u00E1 mikrobiologie a infek\u010Dn\u00ED l\u00E9ka\u0159stv\u00ED" . . "Star\u00FD, Jan" . . . "Invazivn\u00ED mukormyk\u00F3za u d\u011Btsk\u00FDch hematoonkologick\u00FDch pacient\u016F: zku\u0161enosti 2005-2010" . "18" . . "Sedl\u00E1\u010Dek, Petr" . "Chrenkov\u00E1, Vanda" . "Invazivn\u00ED mukormyk\u00F3za u d\u011Btsk\u00FDch hematoonkologick\u00FDch pacient\u016F: zku\u0161enosti 2005-2010"@cs . . "11"^^ . "Hamal, P." . . "13"^^ . . "Mucormycosis is invasive fungal disease representing severe complication of the treatment in patient with haematological disease. The early start of the therapy is necessary for the favourable outcome. The objective of this retrospective work was to determine the frequency, risk factors and the outcome of the invasive mucormycosis in paediatric haematology patients. The study cohort was represented by 399 patients diagnosed for haematological disease in the Department of Paediatric Haematology and Oncology (DPHO), University Hospital Motol, Prague in 2005 \u2013 2010. It was performed retrospective research of the risk factors for mucormycosis development, the clinical symptoms and the radiology and laboratory results. The used therapy and outcome was evaluated too. The findings were analysed using Fisher\u2019s exact test. During the selected period the mucormycosis was detected in 8 patients diagnosed of haematological disease. The incidence of mucormycosis was 1.75 %. These diseases represented 20.6 % of all mycoses. In five patients it was found as isolated infection, in three cases in relationship with other mycosis (once with candidiasis, twice with aspergillosis). The most frequent underlying disease was acute leukaemia; the most common risk factor was severe prolonged neutropenia (median of duration 21.5 days). Three of eight patients survived the mucormycosis, the mortality was 62.5 %. The effective therapy consisted of amphotericin B administration in three patients (p=0.02), in two of them it was in combination with radical surgery. In our cohort we observed uncommonly high contribution comparing to other fungal diseases. Continuing surveillance of mucormycosis in DPHO is needed. We didn\u2019t found significant influence of the combination of radical surgery and amphotericin B administration. Nevertheless according to the published data we consider this approach as optimal management strategy of mucormycosis at the present time."@en . . "Keslov\u00E1, Petra" . "Immunocompromised patient; Invasive fungal diseases; Mucormycosis"@en . . "Ny\u010D, Otakar" . "4" . "Kuncov\u00E1, Kl\u00E1ra" . . "Invasive mucormycosis in pediatric hematology patients - single-center experience 2005-2010"@en . "Invasive mucormycosis in pediatric hematology patients - single-center experience 2005-2010"@en . "RIV/00064203:_____/12:8302" . . "CZ - \u010Cesk\u00E1 republika" . "RIV/00064203:_____/12:8302!RIV13-MZ0-00064203" . . . . "Hub\u00E1\u010Dek, Petr" . . "http://kmil.trios.cz/index.htm" . "Mukormyk\u00F3zy jsou invazivn\u00ED mykotick\u00E1 onemocn\u011Bn\u00ED, kter\u00E1 v\u00FDznamn\u011B komplikuj\u00ED l\u00E9\u010Dbu hematoonkologick\u00FDch pacient\u016F. Nen\u00ED-li v\u010Das zah\u00E1jena \u00FA\u010Dinn\u00E1 terapie, maj\u00ED vysokou m\u00EDru mortality. C\u00EDlem t\u00E9to pr\u00E1ce bylo stanovit frekvenci v\u00FDskytu, identifikovat rizikov\u00E9 faktory a zhodnotit v\u00FDsledky l\u00E9\u010Dby invazivn\u00ED mukormyk\u00F3zy u d\u011Btsk\u00FDch hematoonkologick\u00FDch nemocn\u00FDch. Studovan\u00FD soubor zahrnoval 399 pacient\u016F s diagnostikovan\u00FDm hematologick\u00FDm onemocn\u011Bn\u00EDm na Klinice d\u011Btsk\u00E9 hematologie a onkologie (KDHO) Fakultn\u00ED nemocnice v Motole v letech 2005-2010. Retrospektivn\u011B byly zji\u0161\u0165ov\u00E1ny rizikov\u00E9 faktory pro vznik mukormyk\u00F3z, jejich klinick\u00E9 projevy a s nimi souvisej\u00EDc\u00ED zobrazovac\u00ED a laboratorn\u00ED n\u00E1lezy a charakterizov\u00E1na pou\u017Eit\u00E1 terapie a jej\u00ED v\u00FDsledek. Z\u00EDskan\u00E1 data byla n\u00E1sledn\u011B statisticky vyhodnocena pomoc\u00ED Fisherova exaktn\u00EDho testu. Ve sledovan\u00E9m obdob\u00ED byla mukormyk\u00F3za detekov\u00E1na u 8 pacient\u016F. Incidence tedy byla sledovan\u00E9m obdob\u00ED 1,75 %. Pod\u00EDl t\u011Bchto infekc\u00ED v r\u00E1mci v\u0161ech ostatn\u00EDch invazivn\u00EDch myk\u00F3z \u010Dinil 20,6 %. U p\u011Bti pacient\u016F byla detekovan\u00E1 jako izolovan\u00E1 infekce, u t\u0159\u00ED byla zachycena ve spojitosti s jinou mykotickou infekc\u00ED (1x s kandid\u00F3zou, 2x s aspergil\u00F3zou). Nej\u010Dast\u011Bji se vyskytovala u pacient\u016F s akutn\u00ED leuk\u00E9mi\u00ED, nejb\u011B\u017En\u011Bj\u0161\u00EDm rizikov\u00FDm faktorem byla prolongovan\u00E1 hlubok\u00E1 neutropenie (medi\u00E1n trv\u00E1n\u00ED 21,5 dn\u016F). Infekci p\u0159e\u017Eili 3 z 8 pacient\u016F, mortalita tak dos\u00E1hla 62,5 %. \u00DA\u010Dinn\u00E1 l\u00E9\u010Dba spo\u010D\u00EDvala u t\u0159\u00ED pacient\u016F v pod\u00E1v\u00E1n\u00ED amfotericinu B (p=0.02), u dvou v kombinaci s kompletn\u00EDm chirurgick\u00FDm odstran\u011Bn\u00EDm lo\u017Eiska. V na\u0161em souboru pacient\u016F byl zji\u0161t\u011Bn neobvykle vysok\u00FD pod\u00EDl p\u0159\u00EDpad\u016F mukormyk\u00F3z v porovn\u00E1n\u00ED s ostatn\u00EDmi mykotick\u00FDmi infekcemi, proto je nutn\u00E9 v\u00FDskyt uveden\u00FDch infekc\u00ED na KDHO i nad\u00E1le sledovat. P\u0159esto\u017Ee se n\u00E1m nepoda\u0159ilo p\u0159esv\u011Bd\u010Div\u011B demonstrovat vy\u0161\u0161\u00ED terapeutickou \u00FAsp\u011B\u0161nost kombinace konzervativn\u00EDho a chirurgick\u00E9ho p\u0159\u00EDstupu, na z\u00E1klad\u011B publikovan\u00FDch zku\u0161enost\u00ED se domn\u00EDv\u00E1me, \u017Ee se v sou\u010Dasn\u00E9 dob\u011B jedn\u00E1 o optim\u00E1ln\u00ED strategii l\u00E9\u010Dby t\u00E9to velmi z\u00E1va\u017En\u00E9 infekce." . "I, S" . . "\u0160r\u00E1mkov\u00E1, Lucie" . "Kab\u00ED\u010Dkov\u00E1, Edita" . . . "B\u00E9brov\u00E1, Eli\u0161ka" . . "Mukormyk\u00F3zy jsou invazivn\u00ED mykotick\u00E1 onemocn\u011Bn\u00ED, kter\u00E1 v\u00FDznamn\u011B komplikuj\u00ED l\u00E9\u010Dbu hematoonkologick\u00FDch pacient\u016F. Nen\u00ED-li v\u010Das zah\u00E1jena \u00FA\u010Dinn\u00E1 terapie, maj\u00ED vysokou m\u00EDru mortality. C\u00EDlem t\u00E9to pr\u00E1ce bylo stanovit frekvenci v\u00FDskytu, identifikovat rizikov\u00E9 faktory a zhodnotit v\u00FDsledky l\u00E9\u010Dby invazivn\u00ED mukormyk\u00F3zy u d\u011Btsk\u00FDch hematoonkologick\u00FDch nemocn\u00FDch. Studovan\u00FD soubor zahrnoval 399 pacient\u016F s diagnostikovan\u00FDm hematologick\u00FDm onemocn\u011Bn\u00EDm na Klinice d\u011Btsk\u00E9 hematologie a onkologie (KDHO) Fakultn\u00ED nemocnice v Motole v letech 2005-2010. Retrospektivn\u011B byly zji\u0161\u0165ov\u00E1ny rizikov\u00E9 faktory pro vznik mukormyk\u00F3z, jejich klinick\u00E9 projevy a s nimi souvisej\u00EDc\u00ED zobrazovac\u00ED a laboratorn\u00ED n\u00E1lezy a charakterizov\u00E1na pou\u017Eit\u00E1 terapie a jej\u00ED v\u00FDsledek. Z\u00EDskan\u00E1 data byla n\u00E1sledn\u011B statisticky vyhodnocena pomoc\u00ED Fisherova exaktn\u00EDho testu. Ve sledovan\u00E9m obdob\u00ED byla mukormyk\u00F3za detekov\u00E1na u 8 pacient\u016F. Incidence tedy byla sledovan\u00E9m obdob\u00ED 1,75 %. Pod\u00EDl t\u011Bchto infekc\u00ED v r\u00E1mci v\u0161ech ostatn\u00EDch invazivn\u00EDch myk\u00F3z \u010Dinil 20,6 %. U p\u011Bti pacient\u016F byla detekovan\u00E1 jako izolovan\u00E1 infekce, u t\u0159\u00ED byla zachycena ve spojitosti s jinou mykotickou infekc\u00ED (1x s kandid\u00F3zou, 2x s aspergil\u00F3zou). Nej\u010Dast\u011Bji se vyskytovala u pacient\u016F s akutn\u00ED leuk\u00E9mi\u00ED, nejb\u011B\u017En\u011Bj\u0161\u00EDm rizikov\u00FDm faktorem byla prolongovan\u00E1 hlubok\u00E1 neutropenie (medi\u00E1n trv\u00E1n\u00ED 21,5 dn\u016F). Infekci p\u0159e\u017Eili 3 z 8 pacient\u016F, mortalita tak dos\u00E1hla 62,5 %. \u00DA\u010Dinn\u00E1 l\u00E9\u010Dba spo\u010D\u00EDvala u t\u0159\u00ED pacient\u016F v pod\u00E1v\u00E1n\u00ED amfotericinu B (p=0.02), u dvou v kombinaci s kompletn\u00EDm chirurgick\u00FDm odstran\u011Bn\u00EDm lo\u017Eiska. V na\u0161em souboru pacient\u016F byl zji\u0161t\u011Bn neobvykle vysok\u00FD pod\u00EDl p\u0159\u00EDpad\u016F mukormyk\u00F3z v porovn\u00E1n\u00ED s ostatn\u00EDmi mykotick\u00FDmi infekcemi, proto je nutn\u00E9 v\u00FDskyt uveden\u00FDch infekc\u00ED na KDHO i nad\u00E1le sledovat. P\u0159esto\u017Ee se n\u00E1m nepoda\u0159ilo p\u0159esv\u011Bd\u010Div\u011B demonstrovat vy\u0161\u0161\u00ED terapeutickou \u00FAsp\u011B\u0161nost kombinace konzervativn\u00EDho a chirurgick\u00E9ho p\u0159\u00EDstupu, na z\u00E1klad\u011B publikovan\u00FDch zku\u0161enost\u00ED se domn\u00EDv\u00E1me, \u017Ee se v sou\u010Dasn\u00E9 dob\u011B jedn\u00E1 o optim\u00E1ln\u00ED strategii l\u00E9\u010Dby t\u00E9to velmi z\u00E1va\u017En\u00E9 infekce."@cs . . "Invazivn\u00ED mukormyk\u00F3za u d\u011Btsk\u00FDch hematoonkologick\u00FDch pacient\u016F: zku\u0161enosti 2005-2010"@cs . "142828" . . "Weinbergerov\u00E1, Barbora" .